Blood test may help identify patients at risk for transthyretin amyloid cardiomyopathy

A new multi-center study led by doctors at Boston Medical Center and Columbia University found that having a genetic variant in the prealbumin gene alone is not sufficient for diagnosis of transthyretin amyloid cardiomyopathy in older Black patients.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Columbia University ,American ,Frederickl Ruberg ,Mathew Maurer ,Danielle Ellis ,Journal Of The American Heart Association ,Boston University Chobanian Avedisian School Of Medicine ,Amyloidosis Program ,Nuclear Imaging In Minority Populations ,National Institutes Of Health ,Boston Medical Center ,American Heart Association ,Associate Professor ,Cardiovascular Medicine ,Boston University Chobanian ,Avedisian School ,Cardiac Amyloidosis ,Nuclear Imaging ,Minority Populations ,National Institutes ,New York City ,Arlene Goldstein Professor ,Columbia University Irving Medical Center ,Gene ,Heart ,Heart Failure ,Amyloidosis ,Flood ,Blood Test ,Cardiomyopathy ,Congestive Heart Failure ,Enetic ,Maging ,Medicine ,Protein ,